VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma

Jeremy Abramson • 2 Jun 2015
ASCO 2015
Hodgkin Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Vinblastine

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicenter Phase 2 study that is evaluating brentuximab vedotin, an antibody-drug conjugate, plus doxorubicin (adriamycin), vinblastine and dacarbazine (AVD) for the treatment of patients with non-bulky limited-stage classical Hodgkin lymphoma.

More from Jeremy Abramson

1:25
Bringing CAR T-cells to the second-line setting
Jeremy Abramson • 1 Jun 2018
2:29
Ibrutinib maintenance in MCL
Jeremy Abramson • 7 Dec 2019
2:16
CAR T-cell combination therapies to improve response durability
Jeremy Abramson • 1 Jun 2018
2:27
The EPOCH-R clinical trial in Burkitt lymphoma
Jeremy Abramson • 4 Dec 2015

Related Videos

1:00
Efficacy of haploidentical SCT for R/R classical Hodgkin lymphoma
Ivan Moiseev
2:08
Cellular and targeted therapies for Hodgkin lymphoma
Pauline Brice
1:13
Treatment combinations in Hodgkin lymphoma
Pauline Brice
1:54
Camidanlumab tesirine for R/R non-Hodgkin or Hodgkin lymphomas
Graham Collins

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals